SVRA Stock Analysis: Savara | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.129m USD | 12M Return: 116.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.85M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Savara Inc. (NASDAQ: SVRA) is a small-cap clinical-stage biopharmaceutical company headquartered in Langhorne, Pennsylvania, that focuses on developing treatments for rare respiratory diseases in the United States. Founded in 2007 and listed in 2017, the company operates within the biotechnology sub-industry and, as a clinical-stage issuer, has no approved commercial products and funds its operations primarily through equity and other capital-markets sources while advancing its pipeline.
Its lead product candidate is molgramostim, an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), an ultra-rare lung disorder. Savaras concentration on rare/orphan respiratory indications is consistent with the rare-disease biotech model, which typically pursues regulatory incentives such as Orphan Drug designation to support clinical development and any future commercialization.
- Molgramostim Phase 3 IMPALA-2 topline data readout approaches
- FDA BLA submission and review timeline for aPAP
- Cash burn accelerates raising dilution risk concerns
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -0.02 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -106.9m > Net Income -129.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.3m) vs 12m ago 17.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 209.3m - Total Current Liabilities 15.5m) / Total Assets 221.6m |
| B: -2.91 (Retained Earnings -645.4m / Total Assets 221.6m) |
| C: -0.63 (EBIT TTM -129.5m / Avg Total Assets 205.5m) |
| D: 3.86 (Book Value of Equity 176.0m / Total Liabilities 45.6m) |
| Altman-Z'' = -3.94 = D |
As of July 31, 2026, the stock is trading at USD 5.54 with a total of 1,204,835 shares traded. Over the past week, the price has changed by -3.65%, over one month by -8.13%, over three months by +14.23% and over the past year by +116.41%.
Current recommended Stop Loss: 5.10 (which is 7.9% or 1.5 ATR below the current price).
Savara has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SVRA.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.9 | 97.5% |
P/E Forward = 0.4076
P/S = 145272.6216
P/B = 6.4142
Revenue TTM = 0.0 USD
EBIT TTM = -129.5m USD
EBITDA TTM = -129.3m USD
Long Term Debt = 30.1m USD (from longTermDebt, last quarter)
Short Term Debt = 44.0k USD (from shortTermDebt, last quarter)
Debt = 30.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 44.0k
Net Debt = -172.6m USD (calculated: Debt 30.2m - CCE 202.8m)
Enterprise Value = 956.5m USD (1.13b + Debt 30.2m - CCE 202.8m)
Interest Coverage Ratio = unknown (Ebit TTM -129.5m / Interest Expense TTM 0.0)
EV/FCF = -8.92x (Enterprise Value 956.5m / FCF TTM -107.2m)
FCF Yield = -11.20% (FCF TTM -107.2m / Enterprise Value 956.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 21.1m) / Revenue TTM)
Tobins Q-Ratio = 4.32 (Enterprise Value 956.5m / Total Assets 221.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 30.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -102.3m (EBIT -129.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.44 (Total Current Assets 209.3m / Total Current Liabilities 20.0m)
Debt / Equity = 0.17 (Debt 30.2m / totalStockholderEquity, last quarter 176.0m)
Debt / EBITDA = 1.34 (negative EBITDA) (Net Debt -172.6m / EBITDA -129.3m)
Debt / FCF = 1.61 (negative FCF - burning cash) (Net Debt -172.6m / FCF TTM -107.2m)
Total Stockholder Equity = 148.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.01% (Net Income -129.5m / Total Assets 221.6m)
RoE = -87.19% (Net Income TTM -129.5m / Total Stockholder Equity 148.5m)
RoCE = -72.51% (EBIT -129.5m / Capital Employed (Equity 148.5m + L.T.Debt 30.1m))
RoIC = -49.62% (negative operating profit) (NOPAT -102.3m / Invested Capital 206.2m)
WACC = 8.80% (E(1.13b)/V(1.16b) * Re(9.03%) + D(30.2m)/V(1.16b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.96 | Cagr: 16.44%
[DCF] Fair Price = unknown (Cash Flow -107.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+0.00% | Revisions=-25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.15 | Chg30d=+0.00% | Revisions=-50% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.58 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=-9.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.29 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=+49.3% | GrowthRev=+3169.7%
[Analyst] Revisions Ratio: -62% (up=1, down=9)